The blogosphere has been alight this week with the news that only two candidates remain in the running to become President Barack Obama's new FDA commissioner: Joshua Sharfstein, Baltimore's city health commissioner and linkurl:Robert Califf,;http://www.dukemedicine.org/Leadership/Administration/CaliffRobert%20 Duke University's vice chancellor for clinical research.
linkurl:Peter Pitts,;http://www.cmpi.org/about-us/founders/peter-pitts/ president of the Center for Medicine in the Public Interest (CMPI) and former FDAstaffer, confirmed those rumors, both on linkurl:DrugWonks.com;http://www.drugwonks.com/blog_post/show/6571 -- CMPI's blog -- and when I called him yesterday. Pitts, who has advised the Obama transition team, said that Sharfstein and Califf were the only two names receiving serious consideration.The gravity of Obama's choice seems to increase day by day. Yesterday, the Government Accountability Office linkurl:placed;http://www.gao.gov/products/GAO-09-271 the FDA on a list of "high-risk" areas of the federal government, to attract the attentions of legislators. "FDA needs to, among other things, improve the data it uses to manage the foreign drug inspection program, conduct more...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?